Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $104
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $110 to $104.
Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $110 to $104.